Epitopoietic Research

Executive Summary

Epitopoietic Research (ERC) is a clinical-stage Belgian biopharmaceutical company focused on developing novel immunotherapies for cancer, with a lead program targeting glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The company's proprietary product, Gliovac (ERC1671), is a patented vaccine designed to stimulate the patient's immune system to recognize and attack GBM tumors. Currently in Phase 1 clinical development, Gliovac has shown a favorable safety profile and early signs of efficacy in terms of prolonged survival compared to historical controls. ERC's approach addresses a significant unmet need, as standard of care for GBM offers limited survival benefit and few effective therapies exist. The company operates as a private entity with a lean structure, leveraging its expertise in immunotherapy and vaccine development. Key challenges include advancing the program through later-stage trials, securing funding, and competing in a crowded oncology space. However, if the vaccine continues to demonstrate robust immune responses and survival benefits, Gliovac could become a valuable addition to GBM treatment paradigms.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 interim data readout for Gliovac/ERC1671 in GBM50% success
• Q2 2026Orphan Drug Designation (ODD) from FDA or EMA for Gliovac70% success
• Q3 2026Strategic partnership or licensing deal for Gliovac development30% success